Syndax Pharmaceuticals, Inc. is starting out with a rare subset of acute leukemia patients when it submits revumenib for US Food and Drug Administration review at the end of the year, but it is also aiming for a larger subset that could potentially yield a blockbuster opportunity, one in which others hope to compete as well.
Syndax’s Revumenib Makes Splash At ASH As Company Eyes Blockbuster Opportunity
The company presented data for the menin inhibitor in KMT2Ar acute leukemias in an ASH late-breaker. The larger addressable population, including mNPM1 AML, could be a $2bn opportunity.
More from Clinical Trials
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
More from Conferences
• By
The founder and director of City Therapeutics and founding CEO of Alnylam discussed pressing issues facing the biotech sector in a fireside chat at the recent BIO CEO & Investor Conference.
• By
All the elements for a big M&A year are in place, but political uncertainty and interest rates could push more deals into the second half of the year, according to business development experts at BIO CEO & Investor.
• By
Highlights from the BIO CEO & Investor Conference, held in New York 10-11 February, include the impact of US political changes, Chinese companies entering the obesity race, and IPO pitfalls.